Decent analysis regarding the two companies, how the litigation fared, and what lies ahead for Merck. The article notes:
"Merck is willing to incur the substantial legal costs as part of its strategy to fight each lawsuit in court, arguing its case that it did not play down Vioxx's risks. "I think it beats the alternative," said Dick Clark, Merck chief executive.
This strategy, Merck hopes, will save it billions of dollars in liability costs seen with early big litigation settlements such as Wyeth's almost $20bn fenphen payments."
Go here to read more.
